Annals of Surgical Oncology

, Volume 16, Issue 2, pp 544–545 | Cite as

Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery

  • Dimosthenis Ziogas
  • Eleftheria Ignatiadou
  • Michael Fatouros
Breast Oncology


  1. 1.
    Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRefGoogle Scholar
  2. 2.
    Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. 2005;5:737–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Kurniawan ED, Wong MH, Windle I. Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol. 2008;15:2542–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.Google Scholar
  7. 7.
    Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15:21–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6:308–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4:578–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:1555–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26:4360–1.PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol. 2002;9:607–9.PubMedGoogle Scholar
  15. 15.
    Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002;9:941–3.PubMedGoogle Scholar
  16. 16.
    Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004;11:1030–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med. 2007;357:283–91.PubMedCrossRefGoogle Scholar
  18. 18.
    Ziogas D, Baltogiannis G, Fatouros M, et al. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247:714–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9:828–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002;9:220–1.PubMedCrossRefGoogle Scholar
  23. 23.
    Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998;123:573–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8:587–97.PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8:29–39.PubMedCrossRefGoogle Scholar
  27. 27.
    Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15:956–60.PubMedCrossRefGoogle Scholar
  28. 28.
    Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358:1636.PubMedCrossRefGoogle Scholar
  29. 29.
    Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197.PubMedCrossRefGoogle Scholar
  30. 30.
    Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2008 Aug 23 [Epub ahead of print]. DOI:10.1245/s10434-008-0109-6.

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Dimosthenis Ziogas
    • 1
  • Eleftheria Ignatiadou
    • 1
  • Michael Fatouros
    • 1
  1. 1.Department of Surgery, School of MedicineUniversity of Ioannina Ioannina Greece

Personalised recommendations